MDM2 is a central node in the p53 pathway: 12 Years and counting

Current Cancer Drug Targets

Volumn 5, Issue 1, 2005, Pages 3-8

  Bond, Gareth L ^b   Hu, Wenwei ^b   Levine, Arnold J ^a,b  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

BIOCHEMISTRY; CANCER INHIBITION; CANCER SUSCEPTIBILITY; DRUG TARGETING; FEEDBACK SYSTEM; GENE ACTIVITY; GENE MUTATION; GENETICS; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE MDM2; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; GENES, P53; HUMANS; MICE; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION;

EID: 14644437751     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053332627     Document Type: Review

References (76)

1. Jin, S.; Levine, A. J. The p53 functional circuit. J. Cell Science 2001, 114, 4139-4140.
2. Li, F. P.; Strong, L. C.; Fraumeni, J. F. Jr.; Nelson, C. E.; Kim, D. H.; Kassel, J.; Gryka, M. A.; Bischoff, F. Z.; Tainsky, M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250, 1233-1238.
3. Garber, J. E.; Friend, S. H.; Strong, L. C.; Patenaude, A. F.; Juengst, E. T.; Reilly, P. R.; Correa, P.; Fraumeni, J. F. Jr.; Frebourg, T. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. J. Natl. Cancer Inst. 1992, 84, 1156-1160.
4. Donehower, L. A.; Harvey, M.; Slagle, B. L.; McArthur, M. J.; Montgomery, C. A. Jr.; Butel, J. S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356, 215-221.
5. Lain, S.; Lane, D. Improving cancer therapy by non-genotoxic activation of p53. Eur. J. Cancer 2003, 39, 1053-1060.
6. Linzer, D. I.; Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17, 43-52.
7. Lane, D. P.; Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278, 261-263.
8. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237-1245.
9. Hinds, P. W.; Finlay, C. A.; Quartin, R. S.; Baker, S. J.; Fearon, E. R.; Vogelstein, B.; Levine, A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990, 1, 571-580.
10. Fakharzadeh, S. S.; Trusko, S. P.; George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991, 10, 1565-1569.
11. Cahilly-Snyder, L.; Yang-Feng, T.; Francke, U.; George, D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 1987, 13, 235-244.
12. Eliyahu, D.; Michalovitz, D.; Oren, M. Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 1985, 316, 158-160.
13. Montes de Oca Luna, R.; Wagner, D. S.; Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378, 203-206.
14. Jones, S. N.; Roe, A. E.; Donehower, L. A.; Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378, 206-208.
15. Mendrysa, S. M.; McElwee, M. K.; Michalowski, J.; O'Leary, K. A.; Young, K. M.; Perry, M. E. Mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell Biol. 2003, 23, 462-472.
16. Alt, J. R.; Greiner, T. C.; Cleveland, J. L.; Eischen, C. M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003, 22, 1442-1450.
17. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7, 1126-1132.
18. Barak, Y.; Juven, T.; Haffner, R.; Oren, M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 1993, 12, 461-468.
19. Michael, D.; Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003, 13, 49-58.
20. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
21. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is an ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25-27.
22. Kubbutat, M. H.; Jones, S. N.; Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299-303.
23. Wang, H.; Zeng, X.; Oliver, P.; Le, L. P.; Chen, J.; Chen, L.; Zhou, W.; Agrawal, S.; Zhang, R. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int. J. Oncol. 1999, 15, 653-660.
24. Midgley, C. A.; Desterro, J. M.; Saville, M. K.; Howard, S.; Sparks, A.; Hay, R. T.; Lane, D. P. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000, 19, 2312-2323.
25. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
26. Craig, A. L.; Burch, L.; Vojtesek, B.; Mikutowska, J.; Thompson, A.; Hupp, T. R. Novel phosphorylation sites of human tumor suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 1999, 342, 133-141.
27. Chehab, N. H.; Malikzay, A.; Stavridi, E.S.; Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 1999, 96, 13777-13782.
28. Shieh, S. Y.; Taya, Y.; Prives, C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J. 1999, 18, 1815-1823.
29. Unger, T.; Juven-Gershon, T.; Moallem, E.; Berger, M.; Vogt Sionov, R.; Lozano, G.; Oren, M.; Haupt, Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 1999, 18, 1805-1814.
30. Siliciano, J. D.; Canman, C. E.; Taya, Y.; Sakaguchi, K.; Appella, E.; Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997, 11, 3471-3481.
31. Shieh, S. Y.; Ikeda, M.; Taya, Y.; Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91, 325-334.
32. Ashcroft, M.; Kubbutat, M. H.; Vousden, K. H. Regulation of p53 function and stability by phosphorylation. Mol. Cell Biol. 1999, 19, 1751-1758.
33. Hengstermann, A.; Whitaker, N. J.; Zimmer, D.; Zentgraf, H.; Scheffner, M. Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 1998, 17, 2933-2941.
34. Trotta, R.; Vignudelli, T.; Candini, O.; Intine, R. V.; Pecorari, L.; Guerzoni, C.; Santilli, G.; Byrom, M. W.; Goldoni, S.; Ford, L. P.; Caligiuri, M. A.; Maraia, R. J.; Perrotti, D.; Calabretta, B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003, 3, 145-160.
35. Brown, C. Y.; Mize, G. J.; Pineda, M.; George, D. L.; Morris, D. R. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 1999, 18, 5631-5637.
36. Honda, R.; Yasuda, H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999, 18, 22-27.
37. Tao, W.; Levine, A. J. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 1999, 96, 6937-6941.
38. Weber, J. D.; Taylor, L. J.; Roussel, M. F.; Sherr, C. J.; Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1999, 1, 20-26.
39. Zhang, Y.; Xiong, Y. Mutations in human ARF exon2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 1999, 3, 579-591.
40. Llanos, S.; Clark, P. A.; Rowe, J.; Peters, G. Stabilization of p53 by p 14ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 2001, 3, 445-452.
41. Lomax, M.; Fried, M. Polyoma virus disrupts ARF signaling to p53. Oncogene 2001, 20, 4951-4960.
42. Wang, X.; Michael, D.; de Murcia, G.; Oren, M. p53 Activation by nitric oxide involves down-regulation of Mdm2. J. Biol. Chem. 2002, 277, 15697-15702.
43. Wu, L.; Levine, A. J. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 1997, 3, 441-451.
44. Inoue, T.; Geyer, R. K.; Yu, Z. K.; Maki, C. G. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001, 490, 196-201.
45. Ashcroft, M.; Taya, Y.; Vousden, K. H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell Biol. 2000, 20, 3224-3233.
46. Stommel, J. M.; Wahl, G. M. Accelerated MDM2 autodegradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004, 23, 1547-1556.
47. Lev Bar-Or, R.; Maya, R.; Segel, L. A.; Alon, U.; Levine, A. J.; Oren, M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. USA 2000, 97, 11250-11255.
48. Fu, L.; Minden, M.D.; Benchimol, S. Translational regulation of human p53 gene expression. EMBO J. 1996, 15, 4392-4401.
49. Collister, M.; Lane, D. P.; Kuehl, B. L. Differential expression of p53, p21waf1/cip1 and hdm2 dependent on DNA damage in Bloom's syndrome fibroblasts. Carcinogenesis, 1998, 19, 2115-2120.
50. Ohnishi, T.; Wang, X.; Takahashi, A.; Ohnishi, K.; Ejima, Y. Low-dose-rate radiation attenuates the response of the tumor suppressor TP53. Radiat. Res. 1999, 151, 368-372.
51. Lahav, G.; Rosenfeld, N.; Sigal, A.; Geva-Zatorsky, N.; Levine, A. J.; Elowitz, M. B.; Alon, U. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 2004, 36, 147-150.
52. Cordon-Cardo, C.; Latres, E.; Drobnjak, M.; Oliva, M. R.; Pollack, D.; Woodruff, J. M.; Marechal, V.; Chen, J.; Brennan, M. F.; Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994, 54, 794-799.
53. Leach, F. S.; Tokino, T.; Meltzer, P.; Burrell, M.; Oliner, J. D.; Smith, S.; Hill, D. E.; Sidransky, D.; Kinzler, K. W.; Vogelstein, B. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993, 53, 2231-2234.
54. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
55. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26, 3453-3459.
56. Onel, K.; Cordon-Cardo, C. MDM2 and prognosis. Mol. Cancer Res. 2004, 2, 1-8.
57. Taubert, H.; Koehler, T.; Meye, A.; Bartel, F.; Lautenschlager, C.; Borchert, S.; Bache, M.; Schmidt, H.; Wurl, P. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol. Med. 2000, 6, 50-59.
58. Nakayama, T.; Toguchida, J.; Wadayama, B.; Kanoe, H.; Kotoura, Y.; Sasaki, M. S. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int. J. Cancer 1995, 64, 342-346.
59. Miller, C. W.; Aslo, A.; Won, A.; Tan, M.; Lampkin, B.; Koeffler, H. P. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol. 1996, 122, 559-565.
60. Reifenberger, G.; Liu, L.; Ichimura, K.; Schmidt, E. E.; Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993, 53, 2736-2739.
61. Bueso-Ramos, C. E.; Yang, Y.; deLeon, E.; McCown, P.; Stass, S. A.; Albitar, M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993, 82, 2617-2123.
62. Watanabe, T.; Hotta, T.; Ichikawa, A.; Kinoshita, T.; Nagai, H.; Uchida, T.; Murate, T.; Saito, H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994, 84, 3158-3165.
63. Matsumura, T.; Yoshihama, Y.; Kimura, T.; Shintani, S.; Alcalde, R. E. p53 and MDM2 expression in oral squamous cell carcinoma. Oncology 1996, 53, 308-312.
64. Jones, S. N.; Hancock, A. R.; Vogel, H.; Donehower, L.A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 1998, 95, 15608-15612.
65. Lundgren, K.; Montes de Oca Luna, R.; McNeill, Y. B.; Emerick, E. P.; Spencer, B.; Barfield, C. R.; Lozano, G.; Rosenberg, M. P.; Finlay, C. A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes. Dev. 1997, 11, 714-725.
66. Ganguli, G.; Abecassis, J.; Wasylyk, B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO. J. 2000, 19, 5135-5147.
67. Momand, J.; Wu, H. H.; Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein. Gene. 2000, 242, 15-29.
68. rd.; George, D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994, 9, 2745-2750.
69. Capoulade, C.; Bressac-de Paillerets, B.; Lefrere, I.; Ronsin, M.; Feunteun, J.; Tursz, T.; Wiels, J. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 1998, 16, 1603-1610.
70. Zauberman, A.; Flusberg, D.; Haupt, Y.; Barak, Y.; Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 1995, 23, 2584-2592.
71. Ries, S.; Biederer, C.; Woods, D.; Shifman, O.; Shirasawa, S.; Sasazuki, T.; McMahon, M.; Oren, M.; McCormick, F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103, 321-330.
72. Sheikh, M. S.; Shao, Z. M.; Hussain, A.; Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res., 1993, 53, 3226-3228.
73. Phelps, M.; Darley, M.; Primrose, J. N.; Blaydes, J. P. p53-Independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003, 63, 2616-2623.
74. Lin, J.; Chen, J.; Elenbaas, B.; Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994, 8, 1235-1246.
75. Freedman, D. A.; Epstein, C. B.; Roth, J. C.; Levine, A. J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 1997, 3, 248-259.
76. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.